273 related articles for article (PubMed ID: 33841329)
1. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
4. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
Mansur A; Vaidya A; Turchin A
Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
[TBL] [Abstract][Full Text] [Related]
5. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
6. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
8. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
[TBL] [Abstract][Full Text] [Related]
9. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
10. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
[TBL] [Abstract][Full Text] [Related]
11. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
12. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
13. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
14. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
[TBL] [Abstract][Full Text] [Related]
16. Primary aldosteronism in hypertensive patients: clinical implications and target therapy.
Papanastasiou L; Markou A; Pappa T; Gouli A; Tsounas P; Fountoulakis S; Kounadi T; Tsiama V; Dasou A; Gryparis A; Samara C; Zografos G; Kaltsas G; Chrousos G; Piaditis G
Eur J Clin Invest; 2014 Aug; 44(8):697-706. PubMed ID: 24909545
[TBL] [Abstract][Full Text] [Related]
17. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
[TBL] [Abstract][Full Text] [Related]
19. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
20. Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism.
Rye P; Chin A; Pasieka J; So B; Harvey A; Kline G
J Clin Hypertens (Greenwich); 2015 Jul; 17(7):541-6. PubMed ID: 25756935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
